Initiator Pharma: Strengthened patent protection - Redeye

Redeye comments on Initiator Pharma’s announcement that the EPO has granted two additional European patents covering pudafensine for pain, including vulvodynia, and its immediate-release oral formulation. We view the grants as further strengthening the company’s layered IP protection and supporting the long-term commercial potential of pudafensine, particularly in light of the ongoing phase IIa vulvodynia study.

Länk till analysen i sin helhet: https://www.redeye.se/research/1179893/initiator-pharma-strengthened-patent-protection?utm_source=finwire&utm_medium=RSS